ANGO Quote, Financials, Valuation and Earnings

Globus Medical has a net margin of -18.95% compared to AngioDynamics's net margin of 8.28%. AngioDynamics's return on equity of -56.49% beat Globus Medical's return on equity of 2.27%.

AngioDynamics has a consensus price target of --, signalling upside risk potential of 49.6%. On the other hand Globus Medical has an analysts' consensus of $94.23 which suggests that it could grow by 12.89%. Given that AngioDynamics has higher upside potential than Globus Medical, analysts believe AngioDynamics is more attractive than Globus Medical.

AngioDynamics has a beta of 0.677, which suggesting that the stock is 32.305% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.190, suggesting its more volatile than the S&P 500 by 19.035%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $71M, which are smaller than Globus Medical quarterly revenues of $625.7M. AngioDynamics's net income of -$13.4M is lower than Globus Medical's net income of $51.8M. Notably, AngioDynamics's price-to-earnings ratio is -- while Globus Medical's PE ratio is 124.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.20x versus 4.62x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of -18.95% compared to AngioDynamics's net margin of 1.94%. AngioDynamics's return on equity of -56.49% beat Masimo's return on equity of 5.75%.

AngioDynamics has a consensus price target of --, signalling upside risk potential of 49.6%. On the other hand Masimo has an analysts' consensus of $172.77 which suggests that it could grow by 2.65%. Given that AngioDynamics has higher upside potential than Masimo, analysts believe AngioDynamics is more attractive than Masimo.

AngioDynamics has a beta of 0.677, which suggesting that the stock is 32.305% less volatile than S&P 500. In comparison Masimo has a beta of 1.010, suggesting its more volatile than the S&P 500 by 1.04%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $71M, which are smaller than Masimo quarterly revenues of $504.6M. AngioDynamics's net income of -$13.4M is lower than Masimo's net income of $9.8M. Notably, AngioDynamics's price-to-earnings ratio is -- while Masimo's PE ratio is 116.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.20x versus 4.48x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -18.95% compared to AngioDynamics's net margin of -4291.67%. AngioDynamics's return on equity of -56.49% beat Catheter Precision's return on equity of -65.84%.

AngioDynamics has a consensus price target of --, signalling upside risk potential of 49.6%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 429.24%. Given that Catheter Precision has higher upside potential than AngioDynamics, analysts believe Catheter Precision is more attractive than AngioDynamics.

AngioDynamics has a beta of 0.677, which suggesting that the stock is 32.305% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $71M, which are larger than Catheter Precision quarterly revenues of $96K. AngioDynamics's net income of -$13.4M is lower than Catheter Precision's net income of -$4.1M. Notably, AngioDynamics's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.20x versus 1.01x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -18.95% compared to AngioDynamics's net margin of -17.98%. AngioDynamics's return on equity of -56.49% beat Xtant Medical Holdings's return on equity of -35.98%.

AngioDynamics has a consensus price target of --, signalling upside risk potential of 49.6%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 469.04%. Given that Xtant Medical Holdings has higher upside potential than AngioDynamics, analysts believe Xtant Medical Holdings is more attractive than AngioDynamics.

AngioDynamics has a beta of 0.677, which suggesting that the stock is 32.305% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

AngioDynamics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AngioDynamics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

AngioDynamics quarterly revenues are $71M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. AngioDynamics's net income of -$13.4M is lower than Xtant Medical Holdings's net income of -$5M. Notably, AngioDynamics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AngioDynamics is 1.20x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.